國際簡稱:JCO ONCOL PRACT 參考譯名:Jco 腫瘤學實踐
主要研究方向:ONCOLOGY 非預警期刊 審稿周期:
《Jco 腫瘤學實踐》(Jco Oncology Practice)是一本由LIPPINCOTT WILLIAMS & WILKINS出版的以ONCOLOGY為研究特色的國際期刊,發表該領域相關的原創研究文章、評論文章和綜述文章,及時報道該領域相關理論、實踐和應用學科的最新發現,旨在促進該學科領域科學信息的快速交流。該期刊是一本未開放期刊,近三年沒有被列入預警名單。
JCO Oncology Practice (JCO OP) publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality oncology care with an evolving value-based lens. All content dealing with understanding the provision of care—the mechanics of practice, care delivery, quality improvement, value, and equity—is the purview of JCO OP. JCO OP also addresses an expressed need by practicing physicians to have compressed, expert opinion addressing common clinical problems with perspectives by disease experts. JCO OP is a monthly journal, with a total of 12 issues per year. The Journal's ISSNs are 2688-1535 (online, version of record) and 2688-1527 (print)
JCO OP's content focuses on care delivery from various perspectives, including quality and value of care, improvement science, health services research, business and socioeconomics, performance of clinical trials, professionalism and ethics, and health policy. JCO OP's audience and contributors include all those involved in oncology care delivery, such as physicians, nurses, pharmacists, practice managers, business researchers, policy experts, and payers. Contributions address all settings of oncology care, including institutional, academic, and private practice. JCO OP strives to advance our profession's scientific tradition with new evidence to guide practice, since the details of delivery of care are critical to its quality. While the Journal often focuses on policy and delivery issues in the United States these topics know no geographical or philosophical borders, and all countries/health systems have insights to contribute.
CiteScore | SJR | SNIP | CiteScore 指數 | ||||||||||||||||
6.4 | 1.601 | 1.198 |
|
名詞解釋:CiteScore 是衡量期刊所發表文獻的平均受引用次數,是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據是期刊最近4年(含計算年度)的被引次數除以該期刊近四年發表的文獻數。例如,2022年的 CiteScore 計算方法為:2022年的 CiteScore =2019-2022年收到的對2019-2022年發表的文件的引用數量÷2019-2022年發布的文獻數量 注:文獻類型包括:文章、評論、會議論文、書籍章節和數據論文。
Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
否 | 否 | 醫學 | 3區 | ONCOLOGY 腫瘤學 | 3區 |
Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
否 | 否 | 醫學 | 3區 | ONCOLOGY 腫瘤學 | 4區 |
Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
否 | 否 | 醫學 | 3區 | ONCOLOGY 腫瘤學 | 4區 |
Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
否 | 否 | 醫學 | 3區 | ONCOLOGY 腫瘤學 | 4區 |
Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
否 | 否 | 醫學 | 3區 | ONCOLOGY 腫瘤學 | 4區 |
按JIF指標學科分區 | 收錄子集 | 分區 | 排名 | 百分位 |
學科:ONCOLOGY | SCIE | Q1 | 73 / 322 |
77.5% |
按JCI指標學科分區 | 收錄子集 | 分區 | 排名 | 百分位 |
學科:ONCOLOGY | SCIE | Q2 | 113 / 322 |
65.06% |
Frontiers In Public Health
中科院 3區 JCR Q2
Frontiers In Pharmacology
中科院 2區 JCR Q1
Biomedicine & Pharmacotherapy
中科院 2區 JCR Q1
Discover Oncology
中科院 4區 JCR Q2
Bmc Psychiatry
中科院 2區 JCR Q2
Bmc Neurology
中科院 3區 JCR Q3
Medcomm
中科院 3區 JCR Q1
Journal Of Materials Chemistry B
中科院 3區 JCR Q1
若用戶需要出版服務,請聯系出版商:TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, USA, PA, 19103。